Currently there is no cure for AMN; however,
there are some dietary treatments that patients
are using to help alleviate some of the symptoms
of the disease.
also sometimes take a treatment consisting of
a mixture of glycerol trioleate and glycerol trierucate,
more commonly referred to as Lorenzo's Oil. This
treatment is considered experimental by the FDA
and can cost approximately $440 per month. Because
of its experimental status, most insurance companies
will not cover this treatment.
One biotechnology company working to develop
a treatment for AMN is ReceptoPharm, Inc., a subsidiary
of Nutra Pharma Corporation. The company has two
leading products: RPI-MN and RPI-78M and has just
received MHRA approval to begin Phase IIb human
clinical trials for the treatment of AMN. To learn
more about ReceptoPharm, please click
RPI-78M possesses several desirable properties
as a drug:
- It lacks measurable toxicity but are still
capable of attaching to and affecting the target
site on the nerve cells. This means that patients
- It displays no serious adverse side effects
following years of investigations in humans
- It is extremely stable and resistant to heat,
which gives the drugs a long shelf life. The
drugs' stability has been determined to be over
4 years at room temperature. This is extremely
unusual for a biologic drug.
- It is easy to administer.
- RPI-78M can be administered orally-a first
for a biologic MS drug. This will present MS
patients with additional quality of life benefits
by eliminating the requirement for routine injections.